Tag: Precision medicine
David Epstein launches new cancer startup after Novartis and Seagen career
David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in...
Exploring R&D Strategies of Amgen, Biogen, and Takeda for Challenging Targets
Amgen, Biogen, and Takeda are three biopharma companies facing challenges in developing treatments for obesity and Alzheimer's disease. At the STAT 2024 Summit in Boston, leaders from these companies discussed their research and development...